Editorial
Welcome to the first homepage edition of i2P for 2012.
In many ways it has been a slow start to the New Year because of having to deal with the “leftovers” from 2011.
One of those items for i2P was that a third-party provider to the site did not advise of a code change to the security section in our subscribe panel, creating a range of frustrated subscribers not able to get on board.
We apologise to all those potential subscribers who were unable to register with us in the second half of 2011, but if you try once more you should have no problem.
Columns
Rollo Manning: Pharma-Goss
Linda Bryant: Inside NZ
Loretta Marron BSc: Health Watch
Barry Urquhart: Marketing Focus
Mark Neuenschwander: I`ve been thinking about...Recent Comments
Past Editions
Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Volume 2 Number 3
Volume 2 Number 4
Volume 2 Number 5
Volume 2 Number 6
Volume 2 Number 7
Volume 2 Number 8
Volume 2 Number 9
Volume 2 Number 10
Volume 2 Number 11
Volume 3 Number 1
Volume 3 Number 2
Volume 3 Number 3
Volume 3 Number 4
Volume 3 Number 5
Volume 3 Number 6
Volume 3 Number 7
Volume 3 Number 8
Volume 3 Number 9
Volume 3 Number 10
Volume 3 Number 11
Volume 2012 Number 1
Health Politics
Neil Johnston: Friends of Science in Medicine
Peter Sayers: Confessions of a Frustrated Pharmacist
James Ellerson: $75.5 million in 5CPA lying idle. Why is it so?EPublications
SIGMA Pharmaceuticals suspends share trading before release of revised earnings outlook
Printer-friendly version
Send to friend
PDF version | Staff Writer |
Editing and Researching news and stories about global and local Pharmacy Issues | |
SIGMA Pharmaceuticals suspended today its shares from trade as it delayed releasing revised earnings guidance. Sigma put its shares on a two-day trading halt last Thursday, saying it planned to announce revised earnings guidance before the start of trade today.
However, the company said early today it has requested a further suspension of its shares.
"The suspension is necessary as Sigma expects to make an announcement to the market in relation to revised earnings guidance for the year ended January 31, 2010," Sigma said.
"Sigma expects to make an announcement to the market concerning the revised earnings guidance before the expected date for the release of its preliminary final results.”
Return to homeResearch Reports
Dr Andrew Byrne & Associates: Tranquillizer use rife amongst OTP subjects world-wide, most legally prescribedPractice Development
Neil Retallick: Are the discounters impacting community pharmacy beyond margin erosion? | open full screen
Kay Dunkley - BPharm, Grad Dip Hosp Pharm, Grad Dip Health Admin, MPS, MSHPA: Support services for pharmacists and doctors in the United Kingdom – Part 3 Royal Medical Benevolent Fund | open full screen
Staff Writer: Catch the early wave in 2012 and secure your valuable CPD Credits at the Guild Pharmacy Academy – NSW Convention | open full screen
Information Technology
Dr David More: Australian Health Information Technology LinksIndigenous Health
Preventive Medicine
Gerald Quigley: It’s Time!If any difficulty is found in subscribing, please use the "Contact Us" panel found in the navigation bar with the message "subscribe" and your email address.
Submitted by Brian Flaherty on Tue, 16/03/2010 - 17:06.
How do I explain to my uncle,who was a
pharmacist and used Sigma as his
wholesaler,that they are now worth
buggar-all of sweet nothing.
He has lost his fair share in the Global
Financial Crisis and will be devestated
by the fact that his "beloved" Sigma has
now reduced him to having to apply for
the FULL pension.
What an inglorious way to end his life.
Could Elmo write him a personal
letter apoligizing for their stuff up or
will he pay my uncle out of his own pocket.
Elmo couldn't run a chook raffle in a pub.The trading terms and rebates for
chook raffles would see HIM bankrupt
Post new comment